Last 12 months
Inside the activity.
2 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 2 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Mar 3, 2026 21:34 UTC Amendment |
Francisco DavidChief Financial Officer
|
Tax withholdingClass A Common Stock | 14,687 | $3.84 | $56,398.08 |
DisclosureSEC source: 0002064832-26-000088 · form4a.xml · nonDerivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 731,312 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 21:34 UTC Amendment |
Francisco DavidChief Financial Officer
|
GrantClass A Common Stock | 44,040 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000088 · form4a.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 745,999 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:37 UTC |
Cavorsi RobertVice President, Strategy
|
Tax withholdingClass A Common Stock | 5,442 | $3.73 | $20,298.66 |
DisclosureSEC source: 0002064832-26-000029 · form4.xml · nonDerivative · entry 3 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,507 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:37 UTC |
Cavorsi RobertVice President, Strategy
|
Tax withholdingClass A Common Stock | 5,549 | $3.73 | $20,697.77 |
DisclosureSEC source: 0002064832-26-000029 · form4.xml · nonDerivative · entry 2 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,949 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:37 UTC |
Cavorsi RobertVice President, Strategy
|
Tax withholdingClass A Common Stock | 6,667 | $3.73 | $24,867.91 |
DisclosureSEC source: 0002064832-26-000029 · form4.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,498 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:36 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
Tax withholdingClass A Common Stock | 3,523 | $3.73 | $13,140.79 |
DisclosureSEC source: 0002064832-26-000025 · form4.xml · nonDerivative · entry 4 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 178,061 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:36 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
Tax withholdingClass A Common Stock | 4,100 | $3.73 | $15,293.00 |
DisclosureSEC source: 0002064832-26-000025 · form4.xml · nonDerivative · entry 3 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181,584 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:36 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
Tax withholdingClass A Common Stock | 9,607 | $3.73 | $35,834.11 |
DisclosureSEC source: 0002064832-26-000025 · form4.xml · nonDerivative · entry 2 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,684 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:36 UTC |
Montecalvo Antonio S.Vice President, Health Policy
|
Tax withholdingClass A Common Stock | 1,389 | $3.73 | $5,180.97 |
DisclosureSEC source: 0002064832-26-000025 · form4.xml · nonDerivative · entry 1 Montecalvo Antonio S. · CIK 0001759261 · Vice President, Health Policy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,291 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:37 UTC |
Freedman LoriChief Admin. and Legal Officer
|
Tax withholdingClass A Common Stock | 13,510 | $3.73 | $50,392.30 |
DisclosureSEC source: 0002064832-26-000028 · form4.xml · nonDerivative · entry 4 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 791,717 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:37 UTC |
Freedman LoriChief Admin. and Legal Officer
|
Tax withholdingClass A Common Stock | 12,761 | $3.73 | $47,598.53 |
DisclosureSEC source: 0002064832-26-000028 · form4.xml · nonDerivative · entry 3 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 805,227 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:37 UTC |
Freedman LoriChief Admin. and Legal Officer
|
Tax withholdingClass A Common Stock | 24,428 | $3.73 | $91,116.44 |
DisclosureSEC source: 0002064832-26-000028 · form4.xml · nonDerivative · entry 2 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 817,988 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 16:37 UTC |
Freedman LoriChief Admin. and Legal Officer
|
Tax withholdingClass A Common Stock | 4,043 | $3.73 | $15,080.39 |
DisclosureSEC source: 0002064832-26-000028 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 842,416 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:37 UTC |
Francisco DavidChief Financial Officer
|
Tax withholdingClass A Common Stock | 13,769 | $3.73 | $51,358.37 |
DisclosureSEC source: 0002064832-26-000031 · form4.xml · nonDerivative · entry 4 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 506,647 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:37 UTC |
Francisco DavidChief Financial Officer
|
Tax withholdingClass A Common Stock | 13,369 | $3.73 | $49,866.37 |
DisclosureSEC source: 0002064832-26-000031 · form4.xml · nonDerivative · entry 3 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 520,416 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:37 UTC |
Francisco DavidChief Financial Officer
|
Tax withholdingClass A Common Stock | 21,412 | $3.73 | $79,866.76 |
DisclosureSEC source: 0002064832-26-000031 · form4.xml · nonDerivative · entry 2 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 533,785 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:37 UTC |
Francisco DavidChief Financial Officer
|
Tax withholdingClass A Common Stock | 3,898 | $3.73 | $14,539.54 |
DisclosureSEC source: 0002064832-26-000031 · form4.xml · nonDerivative · entry 1 Francisco David · CIK 0001846282 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 555,197 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:37 UTC |
Bilbo PatrickChief Operating Officer
|
Tax withholdingClass A Common Stock | 15,352 | $3.73 | $57,262.96 |
DisclosureSEC source: 0002064832-26-000030 · form4.xml · nonDerivative · entry 4 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 884,648 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:37 UTC |
Bilbo PatrickChief Operating Officer
|
Tax withholdingClass A Common Stock | 15,617 | $3.73 | $58,251.41 |
DisclosureSEC source: 0002064832-26-000030 · form4.xml · nonDerivative · entry 3 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,000 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:37 UTC |
Bilbo PatrickChief Operating Officer
|
Tax withholdingClass A Common Stock | 28,331 | $3.73 | $105,674.63 |
DisclosureSEC source: 0002064832-26-000030 · form4.xml · nonDerivative · entry 2 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 915,617 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:37 UTC |
Bilbo PatrickChief Operating Officer
|
Tax withholdingClass A Common Stock | 5,114 | $3.73 | $19,075.22 |
DisclosureSEC source: 0002064832-26-000030 · form4.xml · nonDerivative · entry 1 Bilbo Patrick · CIK 0001759203 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 943,948 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:36 UTC |
Gillheeney Gary S.Director · President and CEO
|
Tax withholdingClass A Common Stock | 85,605 | $3.73 | $319,306.65 |
DisclosureSEC source: 0002064832-26-000027 · form4.xml · nonDerivative · entry 4 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,243,917 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:36 UTC |
Gillheeney Gary S.Director · President and CEO
|
Tax withholdingClass A Common Stock | 82,815 | $3.73 | $308,899.95 |
DisclosureSEC source: 0002064832-26-000027 · form4.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,329,522 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:36 UTC |
Gillheeney Gary S.Director · President and CEO
|
Tax withholdingClass A Common Stock | 78,646 | $3.73 | $293,349.58 |
DisclosureSEC source: 0002064832-26-000027 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,412,337 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:36 UTC |
Gillheeney Gary S.Director · President and CEO
|
Tax withholdingClass A Common Stock | 24,340 | $3.73 | $90,788.20 |
DisclosureSEC source: 0002064832-26-000027 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,490,983 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:36 UTC |
Grow BrianChief Commercial Officer
|
Tax withholdingClass A Common Stock | 11,144 | $3.73 | $41,567.12 |
DisclosureSEC source: 0002064832-26-000026 · form4.xml · nonDerivative · entry 4 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 628,418 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:36 UTC |
Grow BrianChief Commercial Officer
|
Tax withholdingClass A Common Stock | 10,559 | $3.73 | $39,385.07 |
DisclosureSEC source: 0002064832-26-000026 · form4.xml · nonDerivative · entry 3 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 639,562 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:36 UTC |
Grow BrianChief Commercial Officer
|
Tax withholdingClass A Common Stock | 18,910 | $3.73 | $70,534.30 |
DisclosureSEC source: 0002064832-26-000026 · form4.xml · nonDerivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,121 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:36 UTC |
Grow BrianChief Commercial Officer
|
Tax withholdingClass A Common Stock | 3,346 | $3.73 | $12,480.58 |
DisclosureSEC source: 0002064832-26-000026 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 669,031 Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 16:19 UTC |
NUSSDORF GLENN HDirector
|
SaleClass A Common Stock | 200,000 | $5.14 | $1,027,060.00 |
DisclosureSEC source: 0002064832-25-000090 · form4.xml · nonDerivative · entry 1 NUSSDORF GLENN H · CIK 0001244191 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,565,591 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.10 to $5.24, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| November 26, 2025 Filed Nov 26, 2025 18:24 UTC |
NUSSDORF GLENN HDirector · 10% owner
|
SaleClass A Common Stock | 187,957 | $5.29 | $994,292.53 |
DisclosureSEC source: 0002064832-25-000040 · form4.xml · nonDerivative · entry 3 NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,765,591 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.25 to $5.39, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 18:24 UTC |
NUSSDORF GLENN HDirector · 10% owner
|
SaleClass A Common Stock | 12,043 | $5.30 | $63,827.90 |
DisclosureSEC source: 0002064832-25-000040 · form4.xml · nonDerivative · entry 2 NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,953,548 Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 18:24 UTC |
NUSSDORF GLENN HDirector · 10% owner
|
SaleClass A Common Stock | 100,000 | $5.34 | $534,000.00 |
DisclosureSEC source: 0002064832-25-000040 · form4.xml · nonDerivative · entry 1 NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,965,591 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.30 to $5.40, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 20:08 UTC |
Grow BrianChief Commercial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,060 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001062993-25-014296 · form4.xml · derivative · entry 3 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 4,060 shares Expires 2025-08-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 20:08 UTC |
Grow BrianChief Commercial Officer
|
Tax withholdingClass A Common Stock | 2,173 | $4.62 | $10,028.40 |
DisclosureSEC source: 0001062993-25-014296 · form4.xml · nonDerivative · entry 2 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 672,377 Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 20:08 UTC |
Grow BrianChief Commercial Officer
|
Exercise / conversionClass A Common Stock | 4,060 | $2.47 | $10,028.20 |
DisclosureSEC source: 0001062993-25-014296 · form4.xml · nonDerivative · entry 1 Grow Brian · CIK 0001759142 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 674,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 16:13 UTC |
Cavorsi RobertVice President, Strategy
|
Tax withholdingClass A Common Stock | 360 | $4.47 | $1,607.40 |
DisclosureSEC source: 0001062993-25-012995 · form4.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,165 Read SEC document |
| June 10, 2025 Filed Nov 3, 2025 17:25 UTC |
NUSSDORF GLENN HDirector · 10% owner
|
SaleClass A Common Stock | 18,620 | $3.56 | $66,255.55 |
DisclosureSEC source: 0002064832-25-000013 · form4.xml · nonDerivative · entry 4 NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998 Disclosed balance after: 335,719 F5 · kind: The reporting person's sale of an aggregate of 22,776 shares of the issuer's Class A common stock on June 9, 2025 and June 10, 2025 reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, with the reporting person's purchase of 22,776 shares of the issuer's Class A common stock on May 15, 2025. The reporting person has paid to the issuer an amount equal to $13,285.24, representing the full amount of the profit realized in connection with the short-swing transaction ($12,971.78) plus interest at the rate of 6% per annum through the date of payment ($313.46). F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.55 to $3.59, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| June 09, 2025 Filed Nov 3, 2025 17:25 UTC |
NUSSDORF GLENN HDirector · 10% owner
|
SaleClass A Common Stock | 4,156 | $3.50 | $14,547.25 |
DisclosureSEC source: 0002064832-25-000013 · form4.xml · nonDerivative · entry 3 NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998 Disclosed balance after: 354,339 F5 · kind: The reporting person's sale of an aggregate of 22,776 shares of the issuer's Class A common stock on June 9, 2025 and June 10, 2025 reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, with the reporting person's purchase of 22,776 shares of the issuer's Class A common stock on May 15, 2025. The reporting person has paid to the issuer an amount equal to $13,285.24, representing the full amount of the profit realized in connection with the short-swing transaction ($12,971.78) plus interest at the rate of 6% per annum through the date of payment ($313.46). F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.50 to $3.505, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| June 06, 2025 Filed Jun 6, 2025 17:44 UTC |
Freedman LoriChief Admin. and Legal Officer
|
PurchaseClass A Common Stock | 9,022 | $2.99 | $26,948.71 |
DisclosureSEC source: 0001062993-25-011161 · form4.xml · nonDerivative · entry 3 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 846,459 F3 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.945 to $3.00, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 17:44 UTC |
Freedman LoriChief Admin. and Legal Officer
|
PurchaseClass A Common Stock | 142,379 | $2.91 | $413,625.23 |
DisclosureSEC source: 0001062993-25-011161 · form4.xml · nonDerivative · entry 2 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 837,437 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.815 to $2.98, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 17:44 UTC |
Freedman LoriChief Admin. and Legal Officer
|
PurchaseClass A Common Stock | 100,863 | $2.82 | $284,716.08 |
DisclosureSEC source: 0001062993-25-011161 · form4.xml · nonDerivative · entry 1 Freedman Lori · CIK 0001410291 · Chief Admin. and Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 695,058 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.74 to $2.875, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| May 15, 2025 Filed Nov 3, 2025 17:25 UTC |
NUSSDORF GLENN HDirector · 10% owner
|
PurchaseClass A Common Stock | 107,494 | $2.99 | $320,998.58 |
DisclosureSEC source: 0002064832-25-000013 · form4.xml · nonDerivative · entry 2 NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998 Disclosed balance after: 358,495 F2 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $2.9725 to $3.00, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| May 14, 2025 Filed Nov 3, 2025 17:25 UTC |
NUSSDORF GLENN HDirector · 10% owner
|
PurchaseClass A Common Stock | 251,001 | $3.09 | $775,040.89 |
DisclosureSEC source: 0002064832-25-000013 · form4.xml · nonDerivative · entry 1 NUSSDORF GLENN H · CIK 0001244191 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Glenn Nussdorf 10 Year Follow On Trust Dated 11-1-1998 Disclosed balance after: 251,001 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.00 to $3.10, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| March 09, 2025 Filed Mar 12, 2025 16:29 UTC |
Cavorsi RobertVice President, Strategy
|
Tax withholdingClass A Common Stock | 61 | $5.16 | $314.76 |
DisclosureSEC source: 0001062993-25-005250 · form4.xml · nonDerivative · entry 2 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,525 Read SEC document |
| March 09, 2025 Filed Mar 12, 2025 16:29 UTC |
Cavorsi RobertVice President, Strategy
|
Tax withholdingClass A Common Stock | 210 | $5.16 | $1,083.60 |
DisclosureSEC source: 0001062993-25-005250 · form4.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,586 Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:08 UTC |
Driscoll Michael JosephDirector
|
SaleClass A Common Stock | 25,000 | $5.10 | $127,535.00 |
DisclosureSEC source: 0001062993-25-004849 · form4.xml · nonDerivative · entry 1 Driscoll Michael Joseph · CIK 0001912097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,879 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.00 to $5.33, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 17:01 UTC |
Cavorsi RobertVice President, Strategy
|
Tax withholdingClass A Common Stock | 667 | $6.21 | $4,142.07 |
DisclosureSEC source: 0001062993-25-004351 · form4.xml · nonDerivative · entry 1 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,796 Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 17:47 UTC |
Lustig GarrettDirector
|
GrantClass A Common Stock | 49,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003220 · form4.xml · nonDerivative · entry 1 Lustig Garrett · CIK 0002044364 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,914 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in full on February 15, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 17:55 UTC |
Cavorsi RobertVice President, Strategy
|
GrantStock Option (Right to Buy) · Derivative | 63,830 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001062993-25-003235 · form4.xml · derivative · entry 2 Cavorsi Robert · CIK 0002020983 · Vice President, Strategy 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,830 Underlying: Class A Common Stock · 63,830 shares Expires 2035-02-19 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.